Apolipoprotein C-II deficiency

H. Inadera*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Apo C-II has a central role in triglyceride metabolism as a cofactor for lipoprotein lipase (LPL), the enzyme that catalyzes the hydrolysis of triglycerides on plasma lipoproteins. Apo C-II deficiency is a rare genetic disorder that is inherited as an autosomal recessive trait. Patients with this syndrome have marked alterations of triglyceride metabolism which include elevated fasting triglycerides, chylomicrons, and VLDL. Clinical features also include lipemia retinalis, eruptive xanthomas, and an increased incidence of pancreatitis. The initial description of the first patient with apo C-II deficiency by Breckenridge et al. established the important role of apo C-II as a cofactor for LPL. Since then, many kindreds with apo C-II deficiency have been described and the underlying molecular defect characterized.

Original languageEnglish
Pages (from-to)3241-3245
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume52
Issue number12
StatePublished - 1994/12

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Apolipoprotein C-II deficiency'. Together they form a unique fingerprint.

Cite this